Degarelix receives final approval for marketing in Europe


We reported last December that the Committee for Medicinal Products for Human Use had adopted a positive opinion and had recommended marketing authorization for degarelix, a second-generation LHRH receptor antagonist, for the treatment of patients with advanced, hormone-dependent prostate cancer.

According to a media release from Ferring Pharmaceuticals earlier today, the European Union has now finalized approval of degarelix for clinical use in Europe.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: